150 related articles for article (PubMed ID: 11151060)
1. Molecular characterization of colorectal neoplasia in translational research.
Grizzle WE; Manne U; Jhala NC; Weiss HL
Arch Pathol Lab Med; 2001 Jan; 125(1):91-8. PubMed ID: 11151060
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1).
Grizzle WE; Manne U; Weiss HL; Jhala N; Talley L
Int J Cancer; 2002 Feb; 97(4):403-9. PubMed ID: 11802199
[TBL] [Abstract][Full Text] [Related]
3. Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients.
Bidgoli SA; Azizi E; Zavarhei MD
Pak J Biol Sci; 2007 Oct; 10(19):3350-5. PubMed ID: 19090149
[TBL] [Abstract][Full Text] [Related]
4. Do young patients with colorectal cancer have a poorer prognosis than old patients?
Li M; Li JY; Zhao AL; Gu J
J Surg Res; 2011 May; 167(2):231-6. PubMed ID: 21316708
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
Das V; Kalita J; Pal M
Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
[TBL] [Abstract][Full Text] [Related]
6. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer.
Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC
Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220
[TBL] [Abstract][Full Text] [Related]
7. p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis.
Mulder JW; Wielenga VJ; Pals ST; Offerhaus GJ
Histochem J; 1997 Jun; 29(6):439-52. PubMed ID: 9248852
[TBL] [Abstract][Full Text] [Related]
8. Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer.
Nasif WA; Lotfy M; El-Sayed IH; El-Kenawy Ael-M; El-Shahat M; El-Hak NG
Med Oncol; 2006; 23(2):237-44. PubMed ID: 16720924
[TBL] [Abstract][Full Text] [Related]
9. Expression of p16INK4a, alone or combined with p53, is predictive of better prognosis in colorectal adenocarcinoma in Tunisian patients.
Miladi-Abdennadher I; Abdelmaksoud-Damak R; Ayadi L; Khabir A; Amouri A; Frikha F; Ellouz S; Frikha M; Sellami-Boudawara T; Mokdad-Gargouri R
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):562-8. PubMed ID: 22095233
[TBL] [Abstract][Full Text] [Related]
10. Design, expression and evaluation of novel chimeric protein constructed from colorectal tumor-associated antigen.
Veisi Malekshahi Z; Amani J; Negahdari B; Rajabibazl M; Ebrahimizadeh W
J Cell Biochem; 2018 Apr; 119(4):3464-3473. PubMed ID: 29144000
[TBL] [Abstract][Full Text] [Related]
11. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.
Chatla C; Jhala NC; Katkoori VR; Alexander D; Meleth S; Grizzle WE; Manne U
Cancer Biomark; 2005; 1(4-5):241-50. PubMed ID: 17192048
[TBL] [Abstract][Full Text] [Related]
12. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.
Tiernan JP; Perry SL; Verghese ET; West NP; Yeluri S; Jayne DG; Hughes TA
Br J Cancer; 2013 Feb; 108(3):662-7. PubMed ID: 23322207
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
15. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
16. The correlation between the immunostains for p53 and Ki67 with bcl-2 expression and classical prognostic factors in colorectal carcinomas.
Gurzu S; Jung J; Mezei T; Pávai Z
Rom J Morphol Embryol; 2007; 48(2):95-9. PubMed ID: 17641794
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.
Mahvi DM; Madsen JA; Witt PL; Sondel PM
Cancer Immunol Immunother; 1995 May; 40(5):311-4. PubMed ID: 7600563
[TBL] [Abstract][Full Text] [Related]
18. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
19. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
20. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
